Review



mrt67307 402  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress mrt67307 402
    Mrt67307 402, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 29 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrt67307 402/product/MedChemExpress
    Average 94 stars, based on 29 article reviews
    mrt67307 402 - by Bioz Stars, 2026-02
    94/100 stars

    Images



    Similar Products

    94
    InvivoGen mrt67307
    The antiproliferative effect of RBN2397 is dependent on DMXAA-induced IFN-I signalling in Py230 cells. ( A ) Proliferation of Py8119 and Py230 cells treated with 0.5, 1, 5, and 10 µg/ml DMXAA. * Significant decrease compared to DMSO, blue for Py8119, red for Py230 cells. IC 50 of Py8119 ( B ) or Py230 ( C ) cells treated with 5–10 µg/mL DMXAA in combination with 0.01 to 1000 nM RBN2397. RBN2397 treatment alone from Fig. C is added for comparison. *Significant decrease compared RBN2397 tested by area under curve, n = 8. ( D ) Fosl1 mRNA levels in Py230 cells treated with DMSO, 10 µg/mL DMXAA, 100 nM RBN2397 or combination for 48 h, and DMSO treated Py8119. ( E ) Py230 cells treated with DMSO, 10 µg/mL DMXAA, 100 nM RBN2397 or combination for 24 h, 48–72 h. Representative image of n = 3, 30 µg protein loaded. Ifnb mRNA level in Py8119 ( F ) and Py230 ( G ) cells treated with 10 µg/mL DMXAA, 100 nM RBN2397, 1 µM <t>MRT67307</t> or combinations for 4 h. ( H ) Proliferation of Py8119 cells treated with DMSO, 1 µM MRT67307, 10 nM RBN2397, 100 nM RBN2397 or combination, n = 4. ( I ) Western blot of Py8119 cells treated 48 h with DMSO, 1 µM MRT67307, 100 nM RBN2397, or combination. Representative image of n = 2, 30 µg of protein was loaded. ( J ) Proliferation of Py230 cells treated with DMSO, 5–10 µg/mL DMXAA in combination with 100 nM RBN2397, 1 µM MRT67307, or combinations of DMXAA, RBN2397 and MRT67307, n = 2. ( K ) Western blot of Py230 cells treated 24 h with DMSO, 10 µg/mL DMXAA + 100 nM RBN2397, 1 µM MRT67307, or combinations. Representative image of n = 2, 30 µg of protein were loaded. * p < 0.05 compared with DMSO. # p < 0.05 compared with the indicated treatments, n = 4
    Mrt67307, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrt67307/product/InvivoGen
    Average 94 stars, based on 1 article reviews
    mrt67307 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress mrt67307 402
    The antiproliferative effect of RBN2397 is dependent on DMXAA-induced IFN-I signalling in Py230 cells. ( A ) Proliferation of Py8119 and Py230 cells treated with 0.5, 1, 5, and 10 µg/ml DMXAA. * Significant decrease compared to DMSO, blue for Py8119, red for Py230 cells. IC 50 of Py8119 ( B ) or Py230 ( C ) cells treated with 5–10 µg/mL DMXAA in combination with 0.01 to 1000 nM RBN2397. RBN2397 treatment alone from Fig. C is added for comparison. *Significant decrease compared RBN2397 tested by area under curve, n = 8. ( D ) Fosl1 mRNA levels in Py230 cells treated with DMSO, 10 µg/mL DMXAA, 100 nM RBN2397 or combination for 48 h, and DMSO treated Py8119. ( E ) Py230 cells treated with DMSO, 10 µg/mL DMXAA, 100 nM RBN2397 or combination for 24 h, 48–72 h. Representative image of n = 3, 30 µg protein loaded. Ifnb mRNA level in Py8119 ( F ) and Py230 ( G ) cells treated with 10 µg/mL DMXAA, 100 nM RBN2397, 1 µM <t>MRT67307</t> or combinations for 4 h. ( H ) Proliferation of Py8119 cells treated with DMSO, 1 µM MRT67307, 10 nM RBN2397, 100 nM RBN2397 or combination, n = 4. ( I ) Western blot of Py8119 cells treated 48 h with DMSO, 1 µM MRT67307, 100 nM RBN2397, or combination. Representative image of n = 2, 30 µg of protein was loaded. ( J ) Proliferation of Py230 cells treated with DMSO, 5–10 µg/mL DMXAA in combination with 100 nM RBN2397, 1 µM MRT67307, or combinations of DMXAA, RBN2397 and MRT67307, n = 2. ( K ) Western blot of Py230 cells treated 24 h with DMSO, 10 µg/mL DMXAA + 100 nM RBN2397, 1 µM MRT67307, or combinations. Representative image of n = 2, 30 µg of protein were loaded. * p < 0.05 compared with DMSO. # p < 0.05 compared with the indicated treatments, n = 4
    Mrt67307 402, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrt67307 402/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    mrt67307 402 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress mrt67307
    DnaJ-induced IFNβ expression is mediated via the TRIF-dependent pathway. ( A , B ) dTHP-1 cells were transfected with siTRIF (150 nM in B ) for 48 h. Knockdown efficiency is shown in the right panel of ( A ). ( C – E ) Cells were pretreated for 1 h with <t>TBK1</t> IH <t>(MRT67307;</t> 200 nM in E ). Following transfection or pretreatment, cells were treated with DnaJ (1 µg/ml) for 4 h ( A , C , D ) or for the indicated durations ( B , E ). ( F , G ) Cells were treated with DnaJ (1 µg/ml) for 4 h ( F ) or for the indicated durations ( G ). IFNβ mRNA and protein levels were analyzed by qPCR and ELISA, respectively; protein expression was assessed by immunoblotting. The samples used for immunoblotting were obtained from the same experiment, and the original blots/gels are shown in the Supplementary Figure. Data in ( A , C , D , F ) are expressed as means ± SD ( n = 3). Immunoblots are representative of three experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001 vs. DnaJ treatment alone ( A , C , D ) or CON ( F ).
    Mrt67307, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrt67307/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    mrt67307 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress tbk1 inhibitor mrt67307
    a , Single-cell RNA-seq Hallmarks IFNα response gene set signature scores in A375 wild-type DFFB and DFFB-KO parental cells and drug-treated cells at the persister and DTEP timepoints. P values were calculated with the two-sided Mann–Whitney test. b , c , Single-cell RNA-seq UMAP of similar numbers of A375 wild-type and DFFB-KO cells at 9 weeks of drug treatment ( b ) with the enriched Hallmarks IFNα response gene set highlighted in red ( c ). d , e , Measurement of the fraction of cells which regrew into DTEP colonies during treatment: A375 DFFB-KO cells treated with 250 nM dabrafenib and 25 nM trametinib for 2 weeks to derive persister cells, then 1 μM JAK inhibitor (JAKi) ruxolitinib was added and all three drugs were maintained for five more weeks ( d ), and PC9 DFFB-KO cells were treated with 300 nM osimertinib and 5 μM ruxolitinib for 5 weeks ( e ). f , Total STAT1 levels in A375 persister cells cotreated for 14 days with 1 μM <t>TBK1</t> inhibitor <t>MRT67307</t> or 1 μM JAKi. g , A375 caspase 9-depleted (pooled KO) and DFFA-CR-expressing parental and persister cells analysed for STAT1. h , PC9 wild-type and DFFB-KO persister cells treated with 500 nM osimertinib analysed for STAT1. i , The A375 DFFB-KO cells treated for 7 days with 250 nM dabrafenib and 25 nM trametinib with and without 1.5 μM of IFNα receptor 1 neutralizing antibody (IFNAR1-nAb) and analysed for total STAT1 expression. j , k , A375 wild-type and STAT1-overexpressing cells ( j ) treated with 250 nM dabrafenib and 25 nM trametinib and analysed for DTEP colony formation ( k ). l , m , PC9 wild-type and STAT1-overexpressing cells ( l ) treated with 300 nM osimertinib and analysed for DTEP colony formation ( m ). In d , e , k and m , n = 3 biological replicates, the mean ± s.d. is shown, and the P values were calculated with the two-tailed Student’s t -test.
    Tbk1 Inhibitor Mrt67307, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tbk1 inhibitor mrt67307/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    tbk1 inhibitor mrt67307 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    Image Search Results


    The antiproliferative effect of RBN2397 is dependent on DMXAA-induced IFN-I signalling in Py230 cells. ( A ) Proliferation of Py8119 and Py230 cells treated with 0.5, 1, 5, and 10 µg/ml DMXAA. * Significant decrease compared to DMSO, blue for Py8119, red for Py230 cells. IC 50 of Py8119 ( B ) or Py230 ( C ) cells treated with 5–10 µg/mL DMXAA in combination with 0.01 to 1000 nM RBN2397. RBN2397 treatment alone from Fig. C is added for comparison. *Significant decrease compared RBN2397 tested by area under curve, n = 8. ( D ) Fosl1 mRNA levels in Py230 cells treated with DMSO, 10 µg/mL DMXAA, 100 nM RBN2397 or combination for 48 h, and DMSO treated Py8119. ( E ) Py230 cells treated with DMSO, 10 µg/mL DMXAA, 100 nM RBN2397 or combination for 24 h, 48–72 h. Representative image of n = 3, 30 µg protein loaded. Ifnb mRNA level in Py8119 ( F ) and Py230 ( G ) cells treated with 10 µg/mL DMXAA, 100 nM RBN2397, 1 µM MRT67307 or combinations for 4 h. ( H ) Proliferation of Py8119 cells treated with DMSO, 1 µM MRT67307, 10 nM RBN2397, 100 nM RBN2397 or combination, n = 4. ( I ) Western blot of Py8119 cells treated 48 h with DMSO, 1 µM MRT67307, 100 nM RBN2397, or combination. Representative image of n = 2, 30 µg of protein was loaded. ( J ) Proliferation of Py230 cells treated with DMSO, 5–10 µg/mL DMXAA in combination with 100 nM RBN2397, 1 µM MRT67307, or combinations of DMXAA, RBN2397 and MRT67307, n = 2. ( K ) Western blot of Py230 cells treated 24 h with DMSO, 10 µg/mL DMXAA + 100 nM RBN2397, 1 µM MRT67307, or combinations. Representative image of n = 2, 30 µg of protein were loaded. * p < 0.05 compared with DMSO. # p < 0.05 compared with the indicated treatments, n = 4

    Journal: Cellular Oncology (Dordrecht, Netherlands)

    Article Title: PARP7 and aryl hydrocarbon receptor differentially regulate mammary cancer cell proliferation and STING-induced type I interferon signalling

    doi: 10.1007/s13402-025-01150-w

    Figure Lengend Snippet: The antiproliferative effect of RBN2397 is dependent on DMXAA-induced IFN-I signalling in Py230 cells. ( A ) Proliferation of Py8119 and Py230 cells treated with 0.5, 1, 5, and 10 µg/ml DMXAA. * Significant decrease compared to DMSO, blue for Py8119, red for Py230 cells. IC 50 of Py8119 ( B ) or Py230 ( C ) cells treated with 5–10 µg/mL DMXAA in combination with 0.01 to 1000 nM RBN2397. RBN2397 treatment alone from Fig. C is added for comparison. *Significant decrease compared RBN2397 tested by area under curve, n = 8. ( D ) Fosl1 mRNA levels in Py230 cells treated with DMSO, 10 µg/mL DMXAA, 100 nM RBN2397 or combination for 48 h, and DMSO treated Py8119. ( E ) Py230 cells treated with DMSO, 10 µg/mL DMXAA, 100 nM RBN2397 or combination for 24 h, 48–72 h. Representative image of n = 3, 30 µg protein loaded. Ifnb mRNA level in Py8119 ( F ) and Py230 ( G ) cells treated with 10 µg/mL DMXAA, 100 nM RBN2397, 1 µM MRT67307 or combinations for 4 h. ( H ) Proliferation of Py8119 cells treated with DMSO, 1 µM MRT67307, 10 nM RBN2397, 100 nM RBN2397 or combination, n = 4. ( I ) Western blot of Py8119 cells treated 48 h with DMSO, 1 µM MRT67307, 100 nM RBN2397, or combination. Representative image of n = 2, 30 µg of protein was loaded. ( J ) Proliferation of Py230 cells treated with DMSO, 5–10 µg/mL DMXAA in combination with 100 nM RBN2397, 1 µM MRT67307, or combinations of DMXAA, RBN2397 and MRT67307, n = 2. ( K ) Western blot of Py230 cells treated 24 h with DMSO, 10 µg/mL DMXAA + 100 nM RBN2397, 1 µM MRT67307, or combinations. Representative image of n = 2, 30 µg of protein were loaded. * p < 0.05 compared with DMSO. # p < 0.05 compared with the indicated treatments, n = 4

    Article Snippet: Dimethyl sulfoxide (DMSO), 5F-203 and paclitaxel was purchased from Merck (Darmstadt, Germany), 6-formylindolo(3,2-b)carbazole (FICZ) from SelleckChem (Houston, TX, USA), RBN2397, BAY2416964 and tapinarof from MedChemExpress (Monmouth Junction, NJ, USA), and DMXAA and MRT67307 from Invivogen (San Diego, CA, USA).

    Techniques: Comparison, Western Blot

    DnaJ-induced IFNβ expression is mediated via the TRIF-dependent pathway. ( A , B ) dTHP-1 cells were transfected with siTRIF (150 nM in B ) for 48 h. Knockdown efficiency is shown in the right panel of ( A ). ( C – E ) Cells were pretreated for 1 h with TBK1 IH (MRT67307; 200 nM in E ). Following transfection or pretreatment, cells were treated with DnaJ (1 µg/ml) for 4 h ( A , C , D ) or for the indicated durations ( B , E ). ( F , G ) Cells were treated with DnaJ (1 µg/ml) for 4 h ( F ) or for the indicated durations ( G ). IFNβ mRNA and protein levels were analyzed by qPCR and ELISA, respectively; protein expression was assessed by immunoblotting. The samples used for immunoblotting were obtained from the same experiment, and the original blots/gels are shown in the Supplementary Figure. Data in ( A , C , D , F ) are expressed as means ± SD ( n = 3). Immunoblots are representative of three experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001 vs. DnaJ treatment alone ( A , C , D ) or CON ( F ).

    Journal: Scientific Reports

    Article Title: Pseudomonas aeruginosa -derived DnaJ functions as a novel immunomodulator inducing IFNβ via CME–SGK1–IRF3 axis in macrophages

    doi: 10.1038/s41598-025-31281-x

    Figure Lengend Snippet: DnaJ-induced IFNβ expression is mediated via the TRIF-dependent pathway. ( A , B ) dTHP-1 cells were transfected with siTRIF (150 nM in B ) for 48 h. Knockdown efficiency is shown in the right panel of ( A ). ( C – E ) Cells were pretreated for 1 h with TBK1 IH (MRT67307; 200 nM in E ). Following transfection or pretreatment, cells were treated with DnaJ (1 µg/ml) for 4 h ( A , C , D ) or for the indicated durations ( B , E ). ( F , G ) Cells were treated with DnaJ (1 µg/ml) for 4 h ( F ) or for the indicated durations ( G ). IFNβ mRNA and protein levels were analyzed by qPCR and ELISA, respectively; protein expression was assessed by immunoblotting. The samples used for immunoblotting were obtained from the same experiment, and the original blots/gels are shown in the Supplementary Figure. Data in ( A , C , D , F ) are expressed as means ± SD ( n = 3). Immunoblots are representative of three experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001 vs. DnaJ treatment alone ( A , C , D ) or CON ( F ).

    Article Snippet: T6167923 (MyD88 inhibitor), MRT67307 (TBK1 inhibitor), and MK-2206 (AKT inhibitor) were purchased from MedChemExpress (Monmouth Junction, NJ, USA).

    Techniques: Expressing, Transfection, Knockdown, Enzyme-linked Immunosorbent Assay, Western Blot

    a , Single-cell RNA-seq Hallmarks IFNα response gene set signature scores in A375 wild-type DFFB and DFFB-KO parental cells and drug-treated cells at the persister and DTEP timepoints. P values were calculated with the two-sided Mann–Whitney test. b , c , Single-cell RNA-seq UMAP of similar numbers of A375 wild-type and DFFB-KO cells at 9 weeks of drug treatment ( b ) with the enriched Hallmarks IFNα response gene set highlighted in red ( c ). d , e , Measurement of the fraction of cells which regrew into DTEP colonies during treatment: A375 DFFB-KO cells treated with 250 nM dabrafenib and 25 nM trametinib for 2 weeks to derive persister cells, then 1 μM JAK inhibitor (JAKi) ruxolitinib was added and all three drugs were maintained for five more weeks ( d ), and PC9 DFFB-KO cells were treated with 300 nM osimertinib and 5 μM ruxolitinib for 5 weeks ( e ). f , Total STAT1 levels in A375 persister cells cotreated for 14 days with 1 μM TBK1 inhibitor MRT67307 or 1 μM JAKi. g , A375 caspase 9-depleted (pooled KO) and DFFA-CR-expressing parental and persister cells analysed for STAT1. h , PC9 wild-type and DFFB-KO persister cells treated with 500 nM osimertinib analysed for STAT1. i , The A375 DFFB-KO cells treated for 7 days with 250 nM dabrafenib and 25 nM trametinib with and without 1.5 μM of IFNα receptor 1 neutralizing antibody (IFNAR1-nAb) and analysed for total STAT1 expression. j , k , A375 wild-type and STAT1-overexpressing cells ( j ) treated with 250 nM dabrafenib and 25 nM trametinib and analysed for DTEP colony formation ( k ). l , m , PC9 wild-type and STAT1-overexpressing cells ( l ) treated with 300 nM osimertinib and analysed for DTEP colony formation ( m ). In d , e , k and m , n = 3 biological replicates, the mean ± s.d. is shown, and the P values were calculated with the two-tailed Student’s t -test.

    Journal: Nature Cell Biology

    Article Title: DNA fragmentation factor B suppresses interferon to enable cancer persister cell regrowth

    doi: 10.1038/s41556-025-01810-x

    Figure Lengend Snippet: a , Single-cell RNA-seq Hallmarks IFNα response gene set signature scores in A375 wild-type DFFB and DFFB-KO parental cells and drug-treated cells at the persister and DTEP timepoints. P values were calculated with the two-sided Mann–Whitney test. b , c , Single-cell RNA-seq UMAP of similar numbers of A375 wild-type and DFFB-KO cells at 9 weeks of drug treatment ( b ) with the enriched Hallmarks IFNα response gene set highlighted in red ( c ). d , e , Measurement of the fraction of cells which regrew into DTEP colonies during treatment: A375 DFFB-KO cells treated with 250 nM dabrafenib and 25 nM trametinib for 2 weeks to derive persister cells, then 1 μM JAK inhibitor (JAKi) ruxolitinib was added and all three drugs were maintained for five more weeks ( d ), and PC9 DFFB-KO cells were treated with 300 nM osimertinib and 5 μM ruxolitinib for 5 weeks ( e ). f , Total STAT1 levels in A375 persister cells cotreated for 14 days with 1 μM TBK1 inhibitor MRT67307 or 1 μM JAKi. g , A375 caspase 9-depleted (pooled KO) and DFFA-CR-expressing parental and persister cells analysed for STAT1. h , PC9 wild-type and DFFB-KO persister cells treated with 500 nM osimertinib analysed for STAT1. i , The A375 DFFB-KO cells treated for 7 days with 250 nM dabrafenib and 25 nM trametinib with and without 1.5 μM of IFNα receptor 1 neutralizing antibody (IFNAR1-nAb) and analysed for total STAT1 expression. j , k , A375 wild-type and STAT1-overexpressing cells ( j ) treated with 250 nM dabrafenib and 25 nM trametinib and analysed for DTEP colony formation ( k ). l , m , PC9 wild-type and STAT1-overexpressing cells ( l ) treated with 300 nM osimertinib and analysed for DTEP colony formation ( m ). In d , e , k and m , n = 3 biological replicates, the mean ± s.d. is shown, and the P values were calculated with the two-tailed Student’s t -test.

    Article Snippet: JAK inhibitor ruxolitinib (HY-50856), TBK1 inhibitor MRT67307 (HY-13018), thapsigargin (HY-13433), ABT-737 (HY-50907), S63845 (HY-100741) and T-5224 (HY-12270) were purchased from MedChemExpress.

    Techniques: RNA Sequencing, MANN-WHITNEY, Expressing, Two Tailed Test